GlassScriptPhysician profile
David K Duncan
NPI 1215116975
$11,745.56
in general payments reported to CMS, 2019-2025
31 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2020: $1,389 · 2021: $1,584 · 2022: $2,157 · 2023: $2,214 · 2024: $1,805 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,453 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,452.84 |
| Education | $155.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,685.25 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $1,207.15 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $1,147.25 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $872.55 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Abbvie INC. | $863.53 | 2019-2025 | Skyrizi, Rinvoq |
| Pfizer INC. | $845.65 | 2019-2025 | |
| Leo Pharma INC. | $823.47 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $703.59 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $657.85 | 2019-2025 | |
| Ucb, INC. | $496.65 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $392.60 | 2022-2025 | Sotyktu |
| Amgen INC. | $345.48 | 2019-2024 | Otezla |
| Almirall LLC | $274.36 | 2019-2023 | Seysara, Klisyri |
| Mayne Pharma Commercial LLC | $250.98 | 2019-2024 | |
| Galderma Laboratories, L.P. | $235.96 | 2019-2025 | Nemluvio, Aklief, Twyneo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $200.76 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $124.61 | 2019-2025 | Cabtreo, Siliq, Jublia |
| Arcutis Biotherapeutics, INC. | $88.68 | 2023-2025 | Zoryve |
| Celgene Corporation | $85.30 | 2019 | |
| Sandoz INC. | $69.46 | 2020-2021 | |
| Nabriva Therapeutics, Plc | $63.32 | 2021-2022 | |
| Incyte Corporation | $61.15 | 2021-2023 | Opzelura |
| Dermavant Sciences, INC. | $60.00 | 2023-2024 | Vtama |
| Kyowa Kirin, INC. | $47.00 | 2023-2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.40 | 2023-2024 | Cyltezo |
| Verrica Pharmaceuticals INC. | $26.15 | 2023 | Ycanth |
| Organon LLC | $25.66 | 2025 | Vtama |
| Dermira, INC. | $23.23 | 2020-2021 | |
| Sebela Pharmaceuticals INC. | $17.17 | 2020 | |
| Fresenius Kabi USA, LLC | $17.13 | 2023 | Idacio |
| Prugen, INC. Pharmaceuticals | $2.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.